Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
1. Regeneron to acquire 23andMe assets for $256 million amid bankruptcy. 2. 23andMe faced challenges generating revenue, leading to its Chapter 11 filing. 3. Regeneron aims to enhance 23andMe's DNA service and health initiatives. 4. Privacy concerns over genetic data still loom, impacting the acquisition review. 5. The deal requires bankruptcy court approval, expected by third quarter 2025.